Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974750 | 0.95 | NAMPT (0.44) | NAMPTBTKSMN1; SMN2NLRP3SNCA | |
| SCHEMBL24974467 | 0.93 | NAMPT (0.42) | NAMPTBTKSMN1; SMN2NLRP3SNCA | |
| SCHEMBL24974740 | 0.86 | NAMPT (0.49) | NAMPTSMN1; SMN2LMNA | |
| SCHEMBL24974786 | 0.82 | NAMPT (0.51) | NAMPTSMN1; SMN2SNCALMNA | |
| SCHEMBL24974640 | 0.78 | NAMPT (0.54) | NAMPTSMN1; SMN2LMNA | |
| SCHEMBL21151296 | 0.77 | BTK (0.49) | NAMPTBTKSMN1; SMN2LMNA | |
| SCHEMBL24974738 | 0.73 | L3MBTL1 (0.38) | NAMPT | |
| SCHEMBL24974582 | 0.69 | TP53 (0.52) | BTK | |
| SCHEMBL21122085 | 0.68 | PKM (0.47) | — | |
| SCHEMBL21151290 | 0.66 | BTK (0.50) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | NAMPT 1356/4885BTK 228/4885SMN1; SMN2 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.